Actions

CD13: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
 
(20 intermediate revisions by the same user not shown)
Line 29: Line 29:


<span style="color:navy">'''Other relevant information:'''</span>  
<span style="color:navy">'''Other relevant information:'''</span>  


Expression is not restricted to myeloid cells, and CD13 is particularly expressed on small intestinal and renal tubular epithelial cells and synaptic membranes from the CNS.
Expression is not restricted to myeloid cells, and CD13 is particularly expressed on small intestinal and renal tubular epithelial cells and synaptic membranes from the CNS.
Line 41: Line 40:
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
|-
!colspan="7"|<span style="font-size:100%">'''CD13 expression: primitive cell types''' ''Click (i) on table for additional information'' </span></font>
!colspan="8"|'''Expression in primitive cell types'''</font>
|-  
|- <span style="font-size:70%">
! AML !! B ALL !! Burkitt || T ALL !! ETP ALL ('''[[ETP ALL|i]]''') !! MPAL ('''[[MPAL|i]]) || Hgns ('''[[Hgns|i]]''')
!AML!!CMML !!B ALL !!BL ||T ALL !!ETP ALL !!MPAL ||Hgn</span>
|-
|-<span style="font-size:70%">
|style="width: 14.25%; background: #006699; color:white"|40-80%
|style="width: 12.5%; background: #004466; color:white"|80-100%*
|style="width: 14.25%; background:#66e0ff; color:black"|5-20%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 14.25%; background:#66e0ff; color:black"|5-20%
|style="width: 12.5%; background: #00b8e6; color:black"|20-40%**
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #66e0ff; color:black"|5-20%
|style="width: 14.25%; background: #00b8e6; color:black"|20-40%
|style="width: 12.5%; background: #66e0ff; color:black"|5-20%
|style="width: 14.25%; background: #00b8e6; color:black"|20-40%
|style="width: 12.5%; background: #00b8e6; color:black"|20-40%**
|style="width: 14.25%; background: #66e0ff; color:black"|<5%
|style="width: 12.5%; background: #00b8e6; color:black"|20-40%**
|style="width: 12.5%; background:#004466; color:white"|80-100%***
|-
|-
|}
|}




<span style="font-size:90%">'''Notes:''' The main application is in AML (see notes for expression). Aberrant expression is seen in ALL - particularly in B-lineage, although it may be less likely in Burkitt lymphoma. CD13 is not generally expressed in T-ALL, but in the correct context CD13 expression can indicate MPAL or ETP-ALL. CD13 is reported to be expressed by some haematognes (click (i) for additional information)
<span style="font-size:90%">'''Notes:''' The main application is in AML. Aberrant expression is seen particularly in B-lineage, although it may be less likely in Burkitt lymphoma. CD13 is not generally expressed in T-ALL. CD13 expression can indicate MPAL or ETP-ALL if other markers suggest this.  




{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
|-
!colspan="7"|'''CD13 expression: mature B cell neoplasms*'''
!colspan="8"|'''Expression in mature B cell neoplasms'''
|-  
|- <span style="font-size:70%">
! CLL !! MCL !!FL!! MZL !! HCL !! LPL !! PCL
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL
|-
|-<span style="font-size:70%">
|style= "width: 14.2%; background: #E6FAFF; color:black"|rare
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 14.2%; background: #E6FAFF; color:black"|rare
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 14.2%; background: #E6FAFF; color:black"|rare
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style= "width: 14.2%; background: #E6FAFF; color:black"|rare
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 14.2%; background: #E6FAFF; color:black"|rare
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 14.2%; background: #E6FAFF; color:black"|rare
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 14.2%; background: #E6FAFF; color:black"|rare
|style="width: 12.5%; background: #00b8e6; color:black"|20-40%
|style="width: 12.5%; background: #00b8e6; color:black"|20-40%
|-
|-
|}
|}


<span style="font-size:90%">'''Notes:''' overall expression is uncommon in mature B-lymphoproliferative disorders, but may occur at plasma cell differentiation</span>
<span style="font-size:90%">'''Notes:''' overall expression is uncommon in mature B-lymphoproliferative disorders, but may occur at plasma cell differentiation</span>
<span style="font-size:90%"> Additional note [[PLL]] and [[vHCL]] are no longer included, click on the name for further information</span>






{| class=wikitable style="text-align: center; font-size:80%; width: 71.4%; height 40px;"
{| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;"
|-
|-
!colspan="7"|'''CD13 expression: mature T cell neoplasms*'''
!colspan="7"|'''CD13 expression: mature T cell neoplasms'''
|-  
|-  
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
! ATLL !! CTCL Sezary !! T-PLL !! T-LGL !! NK-LGL
|-
|-
|style= "width: 20%; background: #FFE4E1; color:black"|limited
|style= "width: 20%; background: #FFE4E1; color:black"|limited
Line 96: Line 99:


----
----
'''KEY'''
<span style="font-size:80%">'''''1. Colour key:''''' ''- the likelihood of any individual case expressing this marker, indicated by colour:''
</span>
{| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
|style= "width: 16.6%; background: #FFE4E1; |Few reported studies (though likely rare)
|}
{| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
|style= "width: 16.6%; background: #E6FAFF; |Expression may be seen, but is rare (<5%)
|}
{| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
|style="width: 16.6%; background: #66e0ff;"|Expression occurs in some cases (5-20%)
|}
{| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
|style="width: 16.6%; background: #00b8e6;"|Expression is likely to be encountered (20-40%)
|}
{| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
|style="width: 16.6%; background: #006699; color:white"|Epression is frequent (40-80%)
|}
{| class=wikitable style="text-align: left; font-size:80%; width: 25%; height: 30px;
|style="width: 16.6%; background: #004466; color:white"|Expect expression in most cases (80-100%)
|}

Latest revision as of 21:37, 4 July 2023


Summary
A useful marker of myeloid lineage although expression depends significantly on stage and type of maturation (see Diagnostic Role). CD13 has recognised aberrant expression in some cases of ALL (particularly B-lineage)



Normal expression and function

CD13 is a cell surface enzyme whose function varies between tissues; its precise function in myeloid cells is unclear. The pattern of expression is similar to other pan-myeloid markers (CD117 and CD33), but with levels generally increasing during maturation (contrasting with CD117 and CD33 whose expression decreases). Maturation of normal myeloid cells may therefore be partly idicated through the relative CD33/13 expression.


Diagnostic role

  • Together with other markers (CD117, CD33 and MPO), CD13 can be used to identify myeloid lineage in acute myeloid leukaemia.
  • CD13 is also expressed by myelomonocytic and monocytic leukaemia cells where a high ratio of CD13/CD33 may help suggest monocytic lineage
  • Expression of CD34 is not required to diagnose AML and is not fully specific - CD13 is often absent on more primitive AML cases as well as on those with erythroid or megakaryoblastic differentiation; while aberrant expression in ALL is recognised to occur in around 30% of patients.

CD13 is often regarded as less specific for myeloid lineage than either CD117 or MPO.


Other relevant information:

Expression is not restricted to myeloid cells, and CD13 is particularly expressed on small intestinal and renal tubular epithelial cells and synaptic membranes from the CNS.



SUMMARY TABLES


Expression in primitive cell types
AML CMML B ALL BL T ALL ETP ALL MPAL Hgn
80-100%* 80-100% 20-40%** 5-20% 5-20% 20-40%** 20-40%** 80-100%***


Notes: The main application is in AML. Aberrant expression is seen particularly in B-lineage, although it may be less likely in Burkitt lymphoma. CD13 is not generally expressed in T-ALL. CD13 expression can indicate MPAL or ETP-ALL if other markers suggest this.


Expression in mature B cell neoplasms
CLL MCL FL MZL HCL DLBCL LPL PCL
<5% <5% <5% <5% <5% <5% 20-40% 20-40%

Notes: overall expression is uncommon in mature B-lymphoproliferative disorders, but may occur at plasma cell differentiation

Additional note PLL and vHCL are no longer included, click on the name for further information


CD13 expression: mature T cell neoplasms
ATLL CTCL Sezary T-PLL T-LGL NK-LGL
limited limited limited limited limited

Notes: There is limited published evidence, but reports suggest expression of CD13 is uncommon in mature T cell malignancy